Pioneering Past Informs Future as Budd Bioworks Unveils 300,000 sq. ft. cGMP BioManufacturing Space in Philadelphia

Published on :

After Decades of Dormancy, Philadelphia’s Powerhouse Budd Plant Presses Ahead as a New Biomanufacturing Center
PHILADELPHIA, PA   July 23, 2021 – A new future is forming around an iconic symbol of Philadelphia’s manufacturing past. The Plymouth Group, in partnership with Centerbridge Partners, L.P., is officially underway on an ambitious biomanufacturing redevelopment plan that puts the life changing therapies developed in Philadelphia’s “Cellicon Valley” on the production line. Spaces will be ready for tenant construction as soon as Q4 of 2021, positioning Philadelphia to meet the swelling demand for cGMP manufacturing nationwide.
The new development will be known as the Budd Campus with the 450,000 square foot Budd Bioworks representing Phase 1 of the project, a life sciences anchor to a 2.4 million square foot adaptive reuse plan that encompasses 6 buildings on over 25 acres in the middle of a major metropolitan area.
Budd Bioworks will comprise 300,000 square feet of cGMP drug manufacturing space along with 150,000 square feet of lab and office space. Residences, restaurants, retail and art activations are planned for subsequent phases within the greater Budd Campus. 
Sitting directly between Philadelphia’s Center City and its suburbs, the former Budd Company Hunting Park Plant holds a significant…

LucasPye and IndyGeneUS AI Forge Partnership To Address Drug Development and the African Diaspora

Published on :

Over the years, minority input in the clinical development of life-saving drugs has been lacking, particularly when it comes to clinical trial participation. That has led to disparities in the efficacy of medications when taken by minority

Developer plans to transform Budd Co. site in Philadelphia into campus for life sciences manufacturing

Published on :

The owner of the sprawling former Budd Co. property in Philadelphia plans to transform it into a biomanufacturing hub, seizing upon Philadelphia’s burgeoning life sciences sector and demand by companies that need the space.

Philadelphia-based LucasPye Bio announces first contract manufacturing partnership

Published on :

LucasPye Bio, a Philadelphia biologics contract development and manufacturing organization, has formed a partnership with Africa-based genomics company IndyGeneUS AI aimed at advancing targeted therapeutics focused on health disparities.

ArriVent Biopharma Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset

Published on :

ArriVent Biopharma, Inc., industry leaders dedicated to accelerating the global development of innovative biopharmaceutical products, today announced the launch of its company with up to $150 million in Series A financing and a potential best-in-class epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), furmonertinib, licensed from Shanghai-based, Allist Pharmaceuticals.

Trevena’s AT1 receptor-selective agonist TRV027 Aimed at COVID-19 in Two Studies

Trevena AT1 TRV027
Published on :

Trevena Inc.’s novel AT1 receptor-selective agonist TRV027 will be included in an international, adaptive Phase II/III study as a potential treatment for COVID-19 patients. The study is being supported by multiple international governments and global research organizations.

The Discovery Labs Signs Foundational Lease with the University of Pennsylvania Gene Therapy Program as Anchor Tenant

Published on :

The Discovery Labs has signed a foundational lease with the University of Pennsylvania Gene Therapy Program (GTP), which will use Discovery Labs’ suburban campus for a portion of its expanding research operations focused on the development of genetic medicines for rare and orphan diseases, as well as acquired and pandemic infectious diseases, such as COVID-19.